MCT-1 (multiple copies in T-cell lymphoma-1), a novel oncogene, was originally identified in T-cell lymphoma. A recent study has demonstrated that MCT-1 is highly expressed in 85% of diffuse large B-cell lymphomas (DLBCL). PKC (protein kinase C) plays an essential role in signal transduction for multiple biologically active substances for activating cellular functions and proliferation. In this study, we found that the mRNA and protein expression levels of MCT-1 were visibly decreased after knocking down PKC by siRNA in SUDHL-4 and OCI-LY8 DLBCL cell lines. A selective PKC inhibitor, sotrastaurin, effectively inhibited cell proliferation and induced cell apoptosis in a dose-and time-dependent manner. Meanwhile, we also observed that the cell cycle was arrested in the G1 phase in sotrastaurintreated cells. In addition, MCT-1 was down-regulated in the sotrastaurin treatment group in vivo. Furthermore, we demonstrated that the PKC inhibitor sotrastaurin induced cell apoptosis and cell cycle arrest in DLBCL cells potentially through regulating the expression of MCT-1. Our data suggest that targeting PKC may be a potential therapeutic approach for lymphomas and related malignancies that exhibit high levels of MCT-1 protein.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults, accounting for nearly 40% of newly diagnosed cases [1] . DLBCL displays remarkable heterogeneity in clinical practice. Despite, more advances in immunochemotherapy, including interval reduction of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and the incorporation of anti-CD20 monoclonal antibodies, long-term remission occurs in only 50% of treated patients [2, 3] . Thus, further research is required to explore relevant molecular targets for improving the treatment of patients with DLBCL.
MCT-1 (multiple copies in T-cell malignancy 1) is an oncogene highly expressed in human T-cell lymphomas [4] . A recent study has confirmed that MCT-1 is highly expressed in 85% of DLBCL, and overexpression of MCT-1 results in a decreased cell doubling time, shortened G1 transition period, and increased cyclin D1 expression with dysregulation at the G1-S checkpoint [5] . MCT-1 plays an important role in lymphomagenesis, including stimulating cell proliferation, suppressing apoptosis, and promoting angiogenesis [6] . Thus, selectively blocking MCT-1 function may be beneficial for the inhibition of its functions in cancer cell proliferation and transformation. However, specific small inhibitory molecules that can directly modulate MCT-1 protein function have not been found.
Protein kinase C (PKC) is a family of single-polypeptide enzymes consisting of an N-terminal regulatory region and a C-terminal catalytic region [7] . PKC plays an essential role in signal transduction for multiple biologically active substances for activating cellular functions and proliferation [8] . A PKC inhibitor has been shown to have antitumor activity in hematologic malignancies [9] . Therefore, we assume that PKC may be the up-stream kinase of MCT-1, and it seems that there is potential to disrupt MCT-1 for the inhibition of cell proliferation through PKC inhibition.
In this study, we detected the level of MCT-1 after knocking down PKC to examine whether MCT-1 is associated with PKC. We further determined whether PKC inhibitor sotrastaurin (STN) has an antitumor activity in vitro and in vivo, and then identified the underlying molecular mechanism. Finally, we established a potential functional interaction between PKC and MCT-1 in DLBCL.
Materials and Methods

Cell culture
The DLBCL cell line OCI-LY8 was a gift from Professor Xiaoyan Zhou from the Department of Pathology, Fudan University Shanghai Cancer Center (Shanghai, China). The SUDHL-4 cell line was purchased from American Type Culture Collection (ATCC, Mananssas, USA). The OCI-LY8 cell line was cultured in Iscove's modified Dulbecco's medium (Gibco, Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin-streptomycin (Gibco), and the SUDHL-4 cell line was cultured in RPMI 1640 (Gibco) containing 10% FBS and 1% penicillin-streptomycin. Cells were incubated in a humidified atmosphere at 37°C in 5% CO 2 .
Reagents STN (40 mM; Sigma, St Louis, USA) was dissolved in dimethyl sulfoxide (DMSO) and stored at −20°C. Antibodies against cleaved caspase-3, ERK1/2, p-ERK1/2, AKT, p-AKT, p53, cleaved caspase-8, and β-actin were purchased from Cell Signaling Technology (Danvers, USA). Antibodies against caspase-9, cyclin D1, and PKC were purchased from Abcam (Cambridge, USA). The anti-MCT-1 antibody was purchased from Thermo Fisher Scientific (Waltham, USA). The Cell Counting Kit-8 (CCK-8) was obtained from Yeasen (Shanghai, China), and the Annexin-V/PI (propidium iodide) apoptosis detection kit was purchased from BD Pharmingen (Franklin Lakes, USA).
Silencing of PKC or MCT-1 in DLBCL cells
SiRNA or control siRNA at a final concentration of 100 nM for PKCβ or MCT-1 were transfected into SUDHL-4 or OCI-LY8 cells cultured in Opti-MEM (Gibco) by means of the Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, USA) for 6 h. Next, these cells were added with culture medium containing 10% FBS at the final concentration and incubated for 42 h. The PKCβ siRNA sequence was 5′-GUCAGAUGCUGAUGUUCCU-3′ and control siRNA sequence was 5′-CAACTGGGTTTGGTGCAG TCACGAA-3′ (Santa Cruz Biotech, Santa Cruz, USA). The MCT-1 siRNA sequence was 5′-CCCTAAGATTACTTCACAA-3′ and control siRNA sequence was 5′-ACTGTTCTATGACTTGTCGTGAATA-3′ (RiboBio, Guangzhou, China).
RNA extraction and quantitative real-time PCR
Total RNA was extracted using the TRIzol reagent (Invitrogen) mixed with DNase I, and 2 μg of RNA was reverse-transcribed using Superscript II RT following the manufacturer's instructions (Life Technologies, Carlsbad, USA). The quantitative real-time PCR (RTqPCR) was performed with a SYBR Green PCR kit (Takara, Shiga, Japan) following the manufacturer's instructions on the ABI PRISM7500 real-time PCR system (ABI, Foster City, USA). The thermal cycling conditions were 95°C for 5 min, followed by 40 cycles of 5 sec at 95°C and then 34 sec at 60°C. The RT-qPCR reactions were performed in a total volume of 20 μl, containing 2 μl of sample cDNA and 0.2 μM of each primer. Data were analyzed using the 2 -ΔΔCt method. β-actin was used as the control. The primers for PCR were as follows: MCT-1 forward 5′-AGGCATTATCTTCATG CTGTCA-3′, reverse 5′-AATGATGGGCTGTGGCATAT-3′; and β-actin forward 5′-CACCAGGGCGTGATGGTGGG-3′, reverse 5′-GA TGCCTCTCTTGCTCTGGGC-3′.
Cell proliferation assay
SUDHL-4 and OCI-LY8 cells (0.1 ml) were seeded into wells of 96-well plates at a density of 2 × 10 5 cells/ml, treated with various concentrations of STN (5, 10, 15, 20, 25, 30, or 40 μM) for 24, 48 or 72 h in a 37°C incubator. At the end of the incubation, 10 μl of CCK-8 solution was added to each well, and the plates were incubated for another 2 h at 37°C. Finally, absorbance was measured at 450 nm using a microplate reader (BioTek, Winooski, USA).
Cell apoptosis assay
Cell apoptosis was measured using the Annexin-V/PI apoptosis detection kit. SUDHL-4 and OCI-LY8 cells (1 ml) were seeded into wells of 24-well plates at a density of 3 × 
Western blot analysis
Cells treated with different doses of STN were lysed in lysis buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol). BCA protein assay kit (Thermo Fisher Scientific) was used to determine the concentration of total cellular protein. Total proteins (30 μg per lane) were electrophoretically separated on 10% or 12.5% sodium dodecyl sulfate-polyacrylamide gel, transferred to polyvinylidene difluoride or nitrocellulose membranes which were then blocked with 5% defatted milk or 5% BSA for 1 h. After that, membranes were probed with the relevant primary antibodies overnight at 4°C. The next day, the membranes were washed with Tween 20-phosphate-buffered saline (PBST) three times and incubated with the fluoresence-conjugated secondary antibodies (anti-rabbit or anti-mouse IgG) for 1 h at room temperature. Membranes were washed with PBST three times for 10 min each and fluoresence was detected by using the Odyssey two-color infrared laser imaging system (LI-COR, Lincoln, USA).
Tumor xenograft mouse model
All animal-related procedures were approved by the Animal Care and Use Committee of Shanghai Tenth People's Hospital (Shanghai, ) were suspended in 100 μl of serum-free culture medium and subcutaneously injected into the upper flank region of nude mice. On the ninth day, eight mice were randomly divided into either the control group (5% DMSO and saline) or the STN group (100 mg/kg/day STN in 5% DMSO saline solution), four mice in each group. Mice were injected with 5% DMSO saline solution or STN for 14 days, and the tumor size and weight were assessed every day. Tumor volume was calculated using the following formula:
/2 (A = largest diameter; B = smallest diameter). At the end of the experimental period, all mice were euthanized and the tumors were collected and imaged. 
Immunohistochemical staining assay
Tumors were dissected and fixed with 4% paraformaldehyde for 24 h and embedded in paraffin. Then, 5-μm-thick sections were prepared and stained with H&E or TUNEL. Immunohistochemistry for PKC or MCT-1 was also performed according to the manufacturer's protocol. The paraffin-embedded tissue samples were dewaxed and incubated with 3% hydrogen peroxide for 30 min. To carry out antigen retrieval, the sections were submerged in citrate buffer and heated in a microwave for 10 min. The sections were incubated with antibodies against PKC or MCT-1 (1:100) overnight at 4°C. Then, the sections were washed with PBS and incubated with HRP-labeled goat anti-mouse secondary antibody for 1 h at room temperature. After that, the slides were stained with 3,3'-diaminobenzidine tetrahydrochloride (DAB) and hematoxylin for visualization.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD) from three independent experiments. Comparisons among the experimental groups were conducted with Student's t-test, and the significance of multiple comparisons was determined using a one-way ANOVA. All statistical analyses were performed with SPSS v20.0 statistical analysis software (IBM Corp., Armonk, USA). P < 0.05 was considered significant.
Results
Knockdown of PKC decreases MCT-1 expression
We first examined whether MCT-1 is associated with PKC. As shown in Fig. 1A ,B, knockdown of PKC decreased the mRNA and protein expression levels of MCT-1 in SUDHL-4 and OCI-LY8 cells, as determined by quantitative real-time PCR (RT-qPCR) and western blot analysis, respectively.
Knockdown of MCT-1 by siRNA induces DLBCL cell apoptosis
MCT-1 is an oncogene originally discovered in T-cell lymphoma, and it plays an important role in tumor cell apoptosis. To test this hypothesis, we transfected MCT-1 siRNA into SUDHL-4 and OCI-LY8 cells. As shown in Fig. 1C , apoptosis was apparent in SUDHL-4 and OCI-LY8 cells with MCT-1 knockdown compared with cells transfected with the control siRNA.
PKC inhibitor STN inhibits cell proliferation
To detect the correlation of PKC with MCT-1, a novel PKC inhibitor STN was used in the cell proliferation assay. As shown in Fig. 2A ,B, DLBCL cell proliferation was decreased with increasing concentrations of STN and prolonged time of treatment, with half-maximal inhibitory concentrations (IC 50 ) of 22.31 and 22.90 μM in SUDHL-4 and OCI-LY8 cells, respectively, at 48 h, suggesting that both cells were inhibited in a dose-and time-dependent manner by STN.
PKC inhibitor STN induces cell apoptosis by downregulating MCT-1
After STN treatment, apoptosis was induced in SUDHL-4 and OCI-LY8 in a dose-and time-dependent manner, which was consistent with the result of the CCK-8 assay (Fig. 3A,B) . The cell apoptosis induced by STN was also characterized by an increasing level of cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9 (Fig. 3C) . We next examined whether MCT-1 associates with PKC. As demonstrated in Fig. 4 , the protein expression levels of MCT-1, p-ERK1/2, and PKC were decreased with increasing concentration of STN. As the ERK1/2 pathway has been confirmed to be in the up-stream of MCT-1, our data may indicate that the decrease in the MCT-1 protein level after PKC inhibition may be through the regulation of the ERK1/2 pathway. PKC inhibitor STN induces cell cycle arrest in G1 phase by down-regulating MCT-1 MCT-1 has been reported to be involved in cell cycle arrest. Therefore, we assessed the cell cycle after treatment with STN at different time points. As shown in Fig. 5A ,B, STN-induced cell cycle arrest in the G1 phase in a time-dependent manner. To determine whether the STN-induced cell cycle arrest is associated with MCT-1, we assessed the protein levels of PKC, MCT-1, cyclin-dependent protein p53, and cyclin D1 by western blot analysis. As demonstrated in Fig. 5C , STN treatment resulted in a decrease of cyclin D1, MCT-1, and PKC proteins, while p53 was increased. These data indicated that STN-induced cell cycle arrest in the G1 phase may be resulted from the increased p53, which may further inhibit MCT-1 function.
In vivo antitumor activity of the PKC inhibitor STN
We subsequently examined whether the PKC inhibitor STN inhibits lymphoma growth by establishing a nude mouse xenograft model. OCI-LY8 cells were injected into six-week-old female BALB/c nude mice. Mice were treated with 5% DMSO and saline or STN via intraperitoneal injection for 14 days. As a result, STN induced a significant decrease in tumor growth (Fig. 6A) , while no significant weight loss was observed among these treated animals (Fig. 6B ). There were no pathological changes in the kidneys and livers of STN-treated animals compared with the control group (Fig. 6C) . As shown in Fig. 6D , more cell necrosis and apoptosis were observed by H&E and TUNEL staining in the tumors of the STN-treated mice compared with those in the control mice. In addition, STN significantly decreased PKC and MCT-1 levels in xenografts, as evidenced by immunohistochemistry assays. These data indicated that the PKC inhibitor effectively inhibits lymphoma growth in vivo potentially by decreasing the level and function of MCT-1.
Discussion
DLBCL is the most common subtype of malignant lymphoma. Despite recent advances with the anti-CD20 antibody rituximab in DLBCL, many patients still suffer from this disease [10] . Therefore, targeted strategies with greater efficacy and less toxicity are urgently required for DLBCL patients. MCT-1 is highly expressed in 85% of DLBCL, and knockdown of MCT-1 dramatically induces cell apoptosis in DLBCL [11] . These lymphoma cells might be more dependent on MCT-1 according to a study by Weinstein and Joe [12] , in which they noted that the growth and survival of cancer cells can be impaired by the inactivation of a single oncogene, which provides a rationale for molecularly-targeted therapy. It was reported that PKC may be located in the crossover point for many signal pathways of cell proliferation [8] . In our study, we found that the knockdown of PKC can decrease the expression of MCT-1. Meanwhile, our data showed that the inhibition of PKC by STN markedly suppressed cell proliferation by inhibiting MCT-1 expression in vitro and in vivo.
Herbert et al. [13] found that MCT-1 is constantly expressed throughout the cell cycle and remains cytoplasmic in human lymphoid tumors, and cells overexpressing MCT-1 have an increased expression of cyclin D1 with dysregulation of the G1-S checkpoint. Cyclin D1 is a nuclear protein required for cell cycle progression in G1 phase [14] . Our results showed that the PKC inhibitor STN induced cell cycle arrest in the G1 phase in a time-dependent manner. These results were characterized by a reduced activity of cyclin D1. Additionally, western blot analysis showed that the expressions of MCT-1 and PKC proteins were suppressed after STN treatment. The tumor suppressor gene p53 has been reported to be related to cell cycle G1 arrest and the inhibition of cell proliferation [15, 16] . A recent work indicated that p53, through regulating the MCT-1 gene promoter, potentially suppresses MCT-1 oncogenicity in a feedback mechanism [17] . To further investigate the underlying mechanism, we detected the expression level of p53 by western blot analysis after cells were treated with STN. The result showed that the protein level of p53 was increased in response to STN treatment. Therefore, we propose that PKC modulates MCT-1 oncogene expression potentially by regulating the p53 activity, contributing to cell cycle arrest in the G1 phase.
Apoptotic defects are required for tumorigenesis [18] . Overexpression of MCT-1 protects against apoptosis in tumor cells [6] . Disruption of MCT-1 function results in an attenuated malignant phenotype in DLBCL [11] . Our data showed that knockdown of MCT-1 induced cell apoptosis in DLBCL cells with high level of MCT-1. We also showed that the PKC inhibitor STN-induced cells apoptosis in a dose-and time-dependent manner. The result was confirmed by an increasing level of cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9. Caspase-3 is the most important component in the apoptotic pathway and can be activated by caspase-8 or caspase-9, the two key proteins of the extrinsic and intrinsic apoptotic pathways, respectively [19] . The protein levels of MCT-1 and p-ERK were both decreased after STN treatment. Moreover, a recently published work inferred that MCT-1 is a substrate of ERK and that ERK modulates both its protein level and activity [11] . Herein, PKC potentially mediates MCT-1 activity through regulating ERK pathway. Further research has demonstrated that activation of AKT promotes many of the processes significant to the malignant phenotype [20] . A prior study has noted that MCT-1 may function as an up-stream regulator of AKT and overexpression of MCT-1 enhances AKT phosphorylation activity [21] . Our results showed that the protein levels of MCT-1 and p-AKT were decreased after PKC inhibition, suggesting that the inhibition of AKT activity may be an important mechanism in cell apoptosis caused by the regulation of MCT-1 activity.
We further investigated whether STN promotes cell death by regulating MCT-1 in vivo. It was found that STN treatment induced a significant reduction in tumor volume compared with the control group. Then, we also observed that MCT-1 was decreased following STN treatment in vivo, suggesting that STN may affect tumor proliferation through mediating MCT-1 in vivo.
In summary, our findings revealed a functional link between PKC and MCT-1. PKC mediates MCT-1 potentially through regulating ERK or p53 activity. We also showed that PKC inhibitor STN has significant antitumor activity in a human lymphoma xenograft model established from DLBCL cell line. Taken together, these data may provide a rationale for the therapeutic use of PKC inhibitors in MCT-1-overexpressing DLBCL.
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